EVEROLIMUS IN THE TREATMENT FOR METASTATIC RENAL CANCER

EVEROLIMUS IN THE TREATMENT FOR METASTATIC RENAL CANCER

Show other versions (1)

Target drugs acting via the HIF/VEGF pathway show a steady-state clinical effect in treating patients with metastatic renal cell carcinoma (RCC). However, to continue therapy in patients with developing resistance in the prolonged use of tyrosine kinase inhibitors remained unsolved, which brought ab...

Full description

Bibliographic Details
Main Authors:	B. Ya. Alekseyev, A. S. Kalpinsky
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Onkourologiâ
Subjects:	renal cell carcinoma tyrosine kinase inhibitors mtor inhibitors everolimus overall and relapse-free survival effectiveness
Online Access:	https://oncourology.abvpress.ru/oncur/article/view/279

Similar Items

EVEROLIMUS IN THE TREATMENT FOR METASTATIC RENAL CANCER
by: B. Ya. Alekseyev, et al.
Published: (2014-07-01)

SEQUENTIAL USE OF TARGET AGENTS AND THEIR COMBINATION IN THE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA
by: B. Ya. Alekseyev, et al.
Published: (2014-08-01)

SEQUENTIAL USE OF TARGET AGENTS AND THEIR COMBINATION IN THE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA
by: B. Ya. Alekseyev, et al.
Published: (2014-08-01)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
by: Mathias Alrø Fichtner Bendtsen, et al.
Published: (2017-08-01)

NEW CAPACITIES OF TARGETED THERAPY FOR METASTATIC RENAL-CELL CARCINOMA
by: B. Ya. Alekseyev, et al.
Published: (2014-08-01)

Treatment of metastatic renal cell carcinoma to the brain: a report of long-term survival following multimodal treatment and sequential use of targeted agents
by: Chih-Chin Yu, et al.
Published: (2014-12-01)

NEW CAPACITIES OF TARGETED THERAPY FOR METASTATIC RENAL-CELL CARCINOMA
by: B. Ya. Alekseyev, et al.
Published: (2014-08-01)

Targeted therapy for metastatic renal cell carcinoma
by: Camillo Porta, et al.
Published: (2014-09-01)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
by: Patrick B. Johnston, et al.
Published: (2018-05-01)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
by: Wu J, et al.
Published: (2020-09-01)

EVEROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS
by: E. I. Prokopenko
Published: (2010-06-01)

Five-year overall survival of metastatic renal cell carcinoma patients treated with everolimus after progression on bevacizumab: a prospective multicenter study CRAD001LRU02T
by: S. Z. Safina, et al.
Published: (2018-01-01)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
by: Fabio Gelsomino, et al.
Published: (2020-05-01)

Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities
by: Julio Pascual, et al.
Published: (2017-05-01)

Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects
by: Simona Granata, et al.
Published: (2016-05-01)

Single nucleotide polymorphisms Rs1045642 C>T genetic alteration in ATP Binding Cassette Subfamily B Member 1 role in increasing everolimus toxicity in metastatic breast cancer
by: Simone Leggeri, et al.
Published: (2020-05-01)

RESULTS OF CLINICAL TRIALS OF MEDICAL TREA TMENT OF RENAL CELL CARCINOMA IN 2014–2015
by: A. M. Popov, et al.
Published: (2016-01-01)

Use of sunitinib in patients with metastatic kidney cancer in real clinical practice
by: B. Ya. Alekseev, et al.
Published: (2016-05-01)

A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey – NOTES study
by: Yalcin Ş, et al.
Published: (2018-03-01)

Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study
by: Shinya Takasaki, et al.
Published: (2019-03-01)

Metastatic Perivascular Epithelioid Cell Tumor Of The Kidney: A Case Report With Emphasis On Response To The Tyrosine-Kinase Inhibitor Sunitinib
by: AlAzab RS, et al.
Published: (2019-11-01)

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
by: Koutsoukos K, et al.
Published: (2017-10-01)

Use of everolimus as an alternative to calcineurin inhibitors in renal allograft recipients: A single South Indian center's experience
by: Manns Manohar John, et al.
Published: (2019-01-01)

Current perspectives on systemic therapy for metastatic non-clear cell renal cell carcinoma
by: J. González, et al.
Published: (2020-12-01)

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
by: Duan F, et al.
Published: (2021-08-01)

CURRENTLY AVAILABLE TREATMENT OPTIONS FOR METASTATIC RENAL CELL CARCINOMA
by: B. Ya. Alekseev, et al.
Published: (2018-10-01)

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma
by: Yang Liu, et al.
Published: (2021-02-01)

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
by: Aleksandra Semeniuk-Wojtaś, et al.
Published: (2016-12-01)

The role of sunitinib in the therapy of metastatic renal cell carcinoma
by: I. G. Rusakov, et al.
Published: (2020-07-01)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
by: Sabrina Rossetti, et al.
Published: (2017-07-01)

Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus
by: Eui Joo Kim, et al.
Published: (2020-11-01)

The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
by: Rohan Garje, et al.
Published: (2020-01-01)

The Changing Therapeutic Landscape of Metastatic Renal Cancer
by: Javier C. Angulo, et al.
Published: (2019-08-01)

Emerging use of everolimus in the treatment of neuroendocrine tumors
by: Gajate P, et al.
Published: (2017-06-01)

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
by: Karam Khaddour, et al.
Published: (2021-06-01)

The Role of Everolimus in Renal Cell Carcinoma
by: Malek Meskawi, et al.
Published: (2015-12-01)

Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
by: Zhiyuan Lin, et al.
Published: (2018-10-01)

Everolimus improved renal function without reducing the size of a kidney angiomyolipoma in a patient with tuberous sclerosis complex: a case report
by: Akira Ashida, et al.
Published: (2018-06-01)

The experience of use of everolimus in patients having undergone to orthotopic liver transplantation
by: V. E. Syutkin, et al.
Published: (2018-08-01)

Progress in targeted therapy for metastatic renal cell carcinoma
by: Yu-Sheng Wang1 ,, et al.
Published: (2019-10-01)